Renji Hospital

Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023

Retrieved on: 
Friday, October 27, 2023
Junshi, Shanghai Jiao Tong University School of Medicine, SSE, Kidney cancer, Cervical cancer, Trial of the century, Manuscript, Axitinib, ESMO, III, Renal cell carcinoma, Lung cancer, Colorectal cancer, Head, Congress, PFS, Renji Hospital, Carcinoma, Impact, Thymus, Research, HIV disease progression rates, RCC, Development, Apoptosis, Clinical trial, Risk, Breast cancer, Immunotherapy, ORR, European Society for Medical Oncology, Patient, Hospital, Death, IRC, Lymphoma, Pharmaceutical industry

At the ESMO Congress 2023, Junshi Bioscience showcased a total of 11 clinical trials involving the groundbreaking immune-oncology drug, toripalimab (anti-PD-1 monoclonal antibody), in the forms of 1 late-breaking abstract, 2 proffered paper oral presentations, and 8 posters.

Key Points: 
  • At the ESMO Congress 2023, Junshi Bioscience showcased a total of 11 clinical trials involving the groundbreaking immune-oncology drug, toripalimab (anti-PD-1 monoclonal antibody), in the forms of 1 late-breaking abstract, 2 proffered paper oral presentations, and 8 posters.
  • “This year’s ESMO Congress highlighted the most recent results from 11 clinical studies conducted with our core product, toripalimab,” said Dr. Jianjun ZOU, Global Research and Development President of Junshi Biosciences.
  • Study findings were unveiled for the first time during a proffered paper session at the ESMO Congress.
  • In terms of safety, toripalimab combined with chemotherapy has a manageable safety profile and no new safety signals were identified.

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab

Retrieved on: 
Wednesday, July 12, 2023
TKI, Malignancy, Renji Hospital, RCC, Clinical trial, Hope, Nephrectomy, Immunotherapy, PFS, Kidney, Shanghai Jiao Tong University School of Medicine, Global Research, Chinese, Death, Development, SSE, Chinese Medical Journal, HIV disease progression rates, Patient, Risk, National Medical Products Administration, IMDC, Carcinoma, Diagnosis, Axitinib, ORR, Safety, Disease, Pharmaceutical industry

Therefore, the need for new treatment options is more urgent for patients with medium and high-risk advanced RCC compared to low-risk patients.

Key Points: 
  • Therefore, the need for new treatment options is more urgent for patients with medium and high-risk advanced RCC compared to low-risk patients.
  • This supplemental new drug application is mainly based on the RENOTORCH study (NCT04394975).
  • The safety profile of toripalimab in the study was consistent with known risks, and no new safety signals were identified.
  • Dr. Jianjun ZOU, the Global Research and Development President of Junshi Biosciences, expressed her enthusiasm regarding the acceptance of this application.

Junshi Biosciences Announces NEJM Publication of Results of Phase 3 Study of VV116 Versus PAXLOVID for Adults at High Risk for Progression to Severe COVID-19

Retrieved on: 
Thursday, December 29, 2022
Fudan University, Clinical trial, HKEX, The New England Journal of Medicine, AE, Article, Renji Hospital, RNA polymerase II, Ruijin Hospital, Smoking, SSE, Overweight, III, NEJM, COVID-19, Transport, Death, Female, FAS, Trial of the century, Shanghai Jiao Tong University School of Medicine, AES, BMI, Patient, Cardiovascular disease, Severe acute respiratory syndrome coronavirus 2, Development, Omicron, Safety, Hypertension, Hospital, Obesity, Șaeș, Diabetes, Incidence, HR, Pharmaceutical industry, Medicine

It is the first time that NEJM published the clinical trial results of China-developed anti-SARS-CoV-2 drug.

Key Points: 
  • It is the first time that NEJM published the clinical trial results of China-developed anti-SARS-CoV-2 drug.
  • The results indicated that the primary endpoint of the study realized the designed noninferiority endpoint, and VV116 group had a shorter time to sustained clinical recovery with less safety concerns as compared with PAXLOVID.
  • Finally, a total of 771 patients (Full Analysis Set, FAS) were treated with VV116 (n = 384) or PAXLOVID (n = 387).
  • The incidence of AEs in VV116 group was lower than that in the PAXLOVID group (all-grade AEs: 67.4% vs. 77.3%, Grade 3 or 4 AE: 2.6% vs. 5.7%).

Concord Medical Announces the Successful Holding of the Second Annual Academic Meeting with the world well-known MD Anderson

Retrieved on: 
Wednesday, November 16, 2022
Monroe Dunaway Anderson, Anderson, Fudan University, Forward-looking statement, Meeting, University, Company, Nursing management, Education, NYSE, CCM, Research, Phrase, The Meeting, Patient, Radiation, Renji Hospital, Hospital, Shanghai Cancer Center, Oncology, MD Anderson Cancer Center, Method, Ruijin Hospital, Cancer, Pharmaceutical industry, Medical device, Medical imaging, Immunotherapy, Bedside

12 experts from MD Anderson participated in the Meeting, including nine of which as guest speakers and three as moderators and opening speakers.

Key Points: 
  • 12 experts from MD Anderson participated in the Meeting, including nine of which as guest speakers and three as moderators and opening speakers.
  • Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical, commented, "I would like to express my heartfelt thanks to the experts who spoke on and participated in the Meeting.
  • MD Anderson is one of the best-known cancer treatment centers globally and the largest cancer center in the United States.
  • Leveraging years of strategic cooperation, MD Anderson and Shanghai Concord Cancer Center successfully cohosted the First Annual Academic Meeting in November 2021.

Nature Cancer Publishes the Collaborative Study Results by Transcenta and Shanghai Jiao Tong University Scientists

Retrieved on: 
Tuesday, May 31, 2022
AR, CRPC, ICB, Population, 1 Canadian Mechanized Brigade Group Headquarters and Signal Squadron, Renji Hospital, Neoplasm, FGFR1, Breast cancer, Shanghai Jiao Tong University, News, Patient, Environment, Lung cancer, Nature, Headquarters, Editorial, Stomach, Esophageal cancer, Research, Hope, IND, Industry, Prostate cancer, Suzhou Industrial Park, Cancer, BMP, Therapy, HKEX, Discovery, List of Nature Research journals, PDX, B cell, Pancreatic cancer, Growth, Castration, Social conditioning, Process, CEO, Jiaotong University, Pharmaceutical industry, Medical imaging

SUZHOU, China, May 30, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that Nature Cancer, an international authoritative journal in oncology field, publishes the results of preclinical studies of Transcenta's first-in-class Gremlin1 targeting antibody (TST003) in the treatment of castration resistant prostate cancer. This research was conducted in collaboration between Transcenta and the team of Professors Helen He Zhu and Wei-Qiang Gao at Renji Hospital, Shanghai JiaoTong University School of Medicine. Professor John T. Isaacs, an internationally renowned expert in prostate cancer research, wrote an editorial and commented that neutralizing antibodies against Gremlin1 could be a potential treatment for androgen receptor-negative/low prostate cancer.

Key Points: 
  • This research was conducted in collaboration between Transcenta and the team of Professors Helen He Zhu and Wei-Qiang Gao at Renji Hospital, Shanghai JiaoTong University School of Medicine.
  • In this study, researchers from Transcenta and Shanghai Jiao Tong University investigated the therapeutic potential of anti-Gremlin1 for prostate cancer in an aggressive mouse model of CRPC (Pbsn-Cre4; Ptenfl/fl; Trp53fl/fl GEMM) and patient derived xenograft (PDX), using TST003, a humanized Gremlin1-targeting antibody, and a surrogate antibody generated by Transcenta.
  • The study results revealed that Gremlin1 protein can promote lineage plasticity and drive castration resistance in prostate cancer.
  • The publication of the study results in Nature Cancer speaks for its novelty and clinical translational value.